This HTML5 document contains 211 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00196/identifier/chebi/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00196/identifier/wikipedia/
n28http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00196/identifier/pharmgkb/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00196/identifier/pdb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00196/identifier/bindingdb/
n29http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB00196/identifier/pubchem-compound/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00196/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00196/identifier/kegg-drug/
n12http://www.rxlist.com/cgi/generic/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00196/identifier/drugbank/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00196/identifier/national-drug-code-directory/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://www.drugs.com/cdi/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00196/identifier/chemspider/
n7http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00196
rdf:type
n3:Drug
n3:description
Triazole antifungal agent that is used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS. [PubChem]
n3:dosage
n28:271B57C2-363D-11E5-9242-09173F13E4C5 n28:271B57C3-363D-11E5-9242-09173F13E4C5 n28:271B57C4-363D-11E5-9242-09173F13E4C5 n28:271B57C5-363D-11E5-9242-09173F13E4C5 n28:271B57C6-363D-11E5-9242-09173F13E4C5 n28:271B57C7-363D-11E5-9242-09173F13E4C5 n28:271B57C8-363D-11E5-9242-09173F13E4C5 n28:271B57C9-363D-11E5-9242-09173F13E4C5 n28:271B57CA-363D-11E5-9242-09173F13E4C5 n28:271B57CB-363D-11E5-9242-09173F13E4C5 n28:271B57CC-363D-11E5-9242-09173F13E4C5 n28:271B57CD-363D-11E5-9242-09173F13E4C5 n28:271B57CE-363D-11E5-9242-09173F13E4C5 n28:271B57CF-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
30 hours (range 20-50 hours)
n3:indication
For the treatment of fungal infections.
n3:manufacturer
n9:271B5783-363D-11E5-9242-09173F13E4C5 n9:271B5784-363D-11E5-9242-09173F13E4C5 n9:271B5782-363D-11E5-9242-09173F13E4C5 n9:271B578B-363D-11E5-9242-09173F13E4C5 n9:271B578C-363D-11E5-9242-09173F13E4C5 n9:271B5789-363D-11E5-9242-09173F13E4C5 n9:271B578A-363D-11E5-9242-09173F13E4C5 n9:271B5787-363D-11E5-9242-09173F13E4C5 n9:271B5788-363D-11E5-9242-09173F13E4C5 n9:271B5785-363D-11E5-9242-09173F13E4C5 n9:271B5786-363D-11E5-9242-09173F13E4C5 n9:271B5793-363D-11E5-9242-09173F13E4C5 n9:271B5794-363D-11E5-9242-09173F13E4C5 n9:271B5791-363D-11E5-9242-09173F13E4C5 n9:271B5792-363D-11E5-9242-09173F13E4C5 n9:271B578F-363D-11E5-9242-09173F13E4C5 n9:271B5790-363D-11E5-9242-09173F13E4C5 n9:271B578D-363D-11E5-9242-09173F13E4C5 n9:271B578E-363D-11E5-9242-09173F13E4C5 n9:271B579B-363D-11E5-9242-09173F13E4C5 n9:271B579C-363D-11E5-9242-09173F13E4C5 n9:271B5799-363D-11E5-9242-09173F13E4C5 n9:271B579A-363D-11E5-9242-09173F13E4C5 n9:271B5797-363D-11E5-9242-09173F13E4C5 n9:271B5798-363D-11E5-9242-09173F13E4C5 n9:271B5795-363D-11E5-9242-09173F13E4C5 n9:271B5796-363D-11E5-9242-09173F13E4C5 n9:271B579D-363D-11E5-9242-09173F13E4C5 n9:271B579E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00196 n29:DB00196
dcterms:title
Fluconazole
adms:identifier
n17:25817 n18:46081 n19:PA449653 n20:3365 n21:0054-0002-85 n22:TPF n23:D00322 n24:3248 n25:Fluconazole n26:DB00196 n27:46505735
n3:mechanismOfAction
Fluconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Fluconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.
n3:packager
n9:271B574E-363D-11E5-9242-09173F13E4C5 n9:271B574F-363D-11E5-9242-09173F13E4C5 n9:271B574C-363D-11E5-9242-09173F13E4C5 n9:271B574D-363D-11E5-9242-09173F13E4C5 n9:271B5752-363D-11E5-9242-09173F13E4C5 n9:271B577C-363D-11E5-9242-09173F13E4C5 n9:271B5750-363D-11E5-9242-09173F13E4C5 n9:271B5751-363D-11E5-9242-09173F13E4C5 n9:271B5746-363D-11E5-9242-09173F13E4C5 n9:271B5747-363D-11E5-9242-09173F13E4C5 n9:271B5745-363D-11E5-9242-09173F13E4C5 n9:271B574A-363D-11E5-9242-09173F13E4C5 n9:271B574B-363D-11E5-9242-09173F13E4C5 n9:271B5748-363D-11E5-9242-09173F13E4C5 n9:271B5749-363D-11E5-9242-09173F13E4C5 n9:271B5771-363D-11E5-9242-09173F13E4C5 n9:271B5772-363D-11E5-9242-09173F13E4C5 n9:271B576F-363D-11E5-9242-09173F13E4C5 n9:271B5770-363D-11E5-9242-09173F13E4C5 n9:271B5775-363D-11E5-9242-09173F13E4C5 n9:271B5776-363D-11E5-9242-09173F13E4C5 n9:271B5773-363D-11E5-9242-09173F13E4C5 n9:271B5774-363D-11E5-9242-09173F13E4C5 n9:271B5769-363D-11E5-9242-09173F13E4C5 n9:271B576A-363D-11E5-9242-09173F13E4C5 n9:271B5767-363D-11E5-9242-09173F13E4C5 n9:271B5768-363D-11E5-9242-09173F13E4C5 n9:271B576D-363D-11E5-9242-09173F13E4C5 n9:271B576E-363D-11E5-9242-09173F13E4C5 n9:271B576B-363D-11E5-9242-09173F13E4C5 n9:271B576C-363D-11E5-9242-09173F13E4C5 n9:271B5761-363D-11E5-9242-09173F13E4C5 n9:271B5762-363D-11E5-9242-09173F13E4C5 n9:271B575F-363D-11E5-9242-09173F13E4C5 n9:271B5760-363D-11E5-9242-09173F13E4C5 n9:271B5765-363D-11E5-9242-09173F13E4C5 n9:271B5766-363D-11E5-9242-09173F13E4C5 n9:271B5763-363D-11E5-9242-09173F13E4C5 n9:271B5764-363D-11E5-9242-09173F13E4C5 n9:271B5759-363D-11E5-9242-09173F13E4C5 n9:271B575A-363D-11E5-9242-09173F13E4C5 n9:271B5757-363D-11E5-9242-09173F13E4C5 n9:271B5758-363D-11E5-9242-09173F13E4C5 n9:271B575D-363D-11E5-9242-09173F13E4C5 n9:271B575E-363D-11E5-9242-09173F13E4C5 n9:271B575B-363D-11E5-9242-09173F13E4C5 n9:271B575C-363D-11E5-9242-09173F13E4C5 n9:271B5755-363D-11E5-9242-09173F13E4C5 n9:271B5756-363D-11E5-9242-09173F13E4C5 n9:271B5753-363D-11E5-9242-09173F13E4C5 n9:271B5754-363D-11E5-9242-09173F13E4C5 n9:271B577F-363D-11E5-9242-09173F13E4C5 n9:271B5780-363D-11E5-9242-09173F13E4C5 n9:271B577D-363D-11E5-9242-09173F13E4C5 n9:271B577E-363D-11E5-9242-09173F13E4C5 n9:271B5781-363D-11E5-9242-09173F13E4C5 n9:271B5779-363D-11E5-9242-09173F13E4C5 n9:271B577A-363D-11E5-9242-09173F13E4C5 n9:271B5777-363D-11E5-9242-09173F13E4C5 n9:271B5778-363D-11E5-9242-09173F13E4C5 n9:271B577B-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
In normal volunteers, fluconazole is cleared primarily by renal excretion, with approximately 80% of the administered dose appearing in the urine as unchanged drug.
n3:synonym
Biozole Fluconazol Elazor Fluconazolum Diflucan Triflucan 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol 2-(2,4-DIFLUOROPHENYL)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol
n3:toxicity
Symptoms of overdose include hallucinations and paranoid behavior.
n5:hasAHFSCode
n6:08-14-08
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
11 to 12%
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Fluconazole.htm
foaf:page
n11:fluconazole.html n12:flucon.htm
n3:IUPAC-Name
n8:271B57D4-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B57DA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B57D9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B57D6-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B57D7-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B57D8-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B57EA-363D-11E5-9242-09173F13E4C5 n8:271B57D2-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B57EC-363D-11E5-9242-09173F13E4C5 n8:271B57D0-363D-11E5-9242-09173F13E4C5 n8:271B57D3-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B57D1-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n7:D01AC15 n7:J02AC01
n3:H-Bond-Acceptor-Count
n8:271B57E0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B57E1-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B57DB-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B57DC-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B57DE-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B57DD-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B57DF-363D-11E5-9242-09173F13E4C5
n3:absorption
90%
n3:affectedOrganism
Fungi
n3:casRegistryNumber
86386-73-4
n3:category
n3:clearance
* 0.23 mL/min/Kg [adults] * 0.18 mL/min/Kg [In premature newborns within 36 hours of birth] * 0.22 mL/min/Kg [In premature newborns 6 days old] * 0.33 mL/min/Kg [In premature newborns 12 days old] * 0.4 mL/min/kg [9 Months-13 yearsreceiving single-oral 2 mg/kg] * 0.51 mL/min/Kg [9 Months-13 yearsreceiving single-oral 8 mg/kg] * 0.49 mL/min/Kg [5-15 yearsreceiving multiple IV 2 mg/kg] * 0.59 mL/min/Kg [5-15 yearsreceiving multiple IV 4 mg/kg] * 0.66 mL/min/Kg [5-15 yearsreceiving multiple IV 8 mg/kg]
n3:containedIn
n4:271B57B6-363D-11E5-9242-09173F13E4C5 n4:271B57B3-363D-11E5-9242-09173F13E4C5 n4:271B57B4-363D-11E5-9242-09173F13E4C5 n4:271B57B9-363D-11E5-9242-09173F13E4C5 n4:271B57BA-363D-11E5-9242-09173F13E4C5 n4:271B57B7-363D-11E5-9242-09173F13E4C5 n4:271B57B8-363D-11E5-9242-09173F13E4C5 n4:271B57AD-363D-11E5-9242-09173F13E4C5 n4:271B57AE-363D-11E5-9242-09173F13E4C5 n4:271B57AB-363D-11E5-9242-09173F13E4C5 n4:271B57AC-363D-11E5-9242-09173F13E4C5 n4:271B57B1-363D-11E5-9242-09173F13E4C5 n4:271B57B2-363D-11E5-9242-09173F13E4C5 n4:271B57AF-363D-11E5-9242-09173F13E4C5 n4:271B57B0-363D-11E5-9242-09173F13E4C5 n4:271B57A5-363D-11E5-9242-09173F13E4C5 n4:271B57A6-363D-11E5-9242-09173F13E4C5 n4:271B57A3-363D-11E5-9242-09173F13E4C5 n4:271B57A4-363D-11E5-9242-09173F13E4C5 n4:271B57A9-363D-11E5-9242-09173F13E4C5 n4:271B57AA-363D-11E5-9242-09173F13E4C5 n4:271B57A7-363D-11E5-9242-09173F13E4C5 n4:271B57A8-363D-11E5-9242-09173F13E4C5 n4:271B57A1-363D-11E5-9242-09173F13E4C5 n4:271B57A2-363D-11E5-9242-09173F13E4C5 n4:271B579F-363D-11E5-9242-09173F13E4C5 n4:271B57A0-363D-11E5-9242-09173F13E4C5 n4:271B57BD-363D-11E5-9242-09173F13E4C5 n4:271B57BE-363D-11E5-9242-09173F13E4C5 n4:271B57BB-363D-11E5-9242-09173F13E4C5 n4:271B57BC-363D-11E5-9242-09173F13E4C5 n4:271B57C1-363D-11E5-9242-09173F13E4C5 n4:271B57BF-363D-11E5-9242-09173F13E4C5 n4:271B57C0-363D-11E5-9242-09173F13E4C5 n4:271B57B5-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n8:271B57E6-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B57E8-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B57E9-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B57EB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B57E5-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B57E4-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B57E7-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B57D5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B57E2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B57E3-363D-11E5-9242-09173F13E4C5